Industry experts are set to discuss the latest developments in Drug Discovery Chemistry at the 3rd Annual Drug Discovery Chemistry Conference 2019, in London.
LONDON, LONDON, UNITED KINGDOM, December 19, 2018 /EINPresswire.com/ —
Industry experts are set to discuss on the latest developments in the field of Drug Discovery Chemistry at the 3rd Annual Drug Discovery Chemistry Conference 2019, taking place in London, UK.
There is unwavering pressure on drug discovery scientists to be more innovative and creative whilst at the same time be more efficient in discovering a higher number of successful drug candidates. In the past two years the conference and workshop had been a success, providing delegates with an opportunity to discuss, learn and gain insight into the latest industry topics.
For this reason, SMi encourages industry peers to attend the 3rd Annual Drug Discovery Chemistry Conference (http://www.drug-discovery.co.uk/PR2) taking place on 18th and 19th March 2019 in London, UK.
Since the last featured speaker interviews, SMi Pharma has had the opportunity to sit down with two other expert speakers from GSK and F Hoffman-La Roche to discuss some of the challenges they face in the industry and their strategies for overcoming them. The following are excerpts from those Q&A sessions:
An interview with Markus Queisser, Scientific Leader, GlaxoSmithKline:
Which emerging advances in the field are you most excited about?
"I am very excited about the emerging PROTAC testing combined with pharmacology data and the potential PD/PK disconnect, demonstrating potential benefits in vivo. The whole industry is waiting for the first clinical trial studies using this new modality."
An interview with Hasane Ratni, Expert Scientist, F Hoffman-La Roche:
What, in your opinion, are the biggest challenges drug discovery scientists are facing currently?
"Certainly, the increased difficulties/hurdles to reach the market, the capacities to integrate the large volume of data, to visualise them and the pressure to reduce timelines as much as possible.
I am very excited about the emerging PROTAC testing combined with pharmacology data and the potential PD/PK disconnect, demonstrating potential benefits in vivo. The whole industry is waiting for the first clinical trial studies using this new modality."
To view the full interviews and latest brochure with the two-day agenda, full speaker line-up and post-workshop details, please visit: http://www.drug-discovery.co.uk/PR2
An interactive half day post-conference workshop will take place on 20th March led by Dr. Nick Camp, Drug Discovery Consultant at Nick Camp Consulting Ltd. The workshop will focus on Artificial Intelligence in Drug Discovery discussing upon current opportunities, challenges and future direction for this technology.
Register by the 31st January to save £100 on your booking here http://www.drug-discovery.co.uk/PR2
Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email email@example.com
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or firstname.lastname@example.org
Drug Discovery Chemistry
Conference: 18th & 19th March 2019
Half-day post-conference workshop: 20th March 2019, 8:30am to 12:30pm
Copthorne Tara Hotel, London, UK
Follow us @SMiPharm on Twitter
—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
email us here
Source: EIN Presswire